StreetInsider.com News Articles

Form 4 Oruka Therapeutics, Inc. For: Oct 15 Filed by: Goncalves Joana

Thu, 15 Oct 2026 18:15:00 -0400

si-local-file:///var/storage/secattach/20261015/27194390.html

Form 144 Oruka Therapeutics, Inc. Filed by: Goncalves Joana

Thu, 15 Oct 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20261015/27193890.html

Form 4 Oruka Therapeutics, Inc. For: Oct 12 Filed by: Agarwal Arjun

Tue, 13 Oct 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20261013/27181593.html

Form 144 Oruka Therapeutics, Inc. Filed by: Agarwal Arjun

Tue, 13 Oct 2026 08:24:00 -0400

si-local-file:///var/storage/secattach/20261013/27177750.html

Piper Sandler: 'We believe now is the time to own Oruka Therapeutics (ORKA)'

Wed, 07 Oct 2026 09:15:54 -0400

Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $180.00 price target on Oruka Therapeutics (NASDAQ: ORKA).

The analyst commented: "A Rising Tide of Catalysts Across ORKA-001 & ORKA-002 in 4Q26/1H27; ORKA is up ~290% in the last 12-months (vs ~47% XBI) which is driven by their catalystpacked pipeline with assets that appear highly de-risked for success. Accordingly, we highlight ORKA-001's (anti-IL-23p19) Ph2a EVERLAST-A 52-week data upcoming in December, where we have high PoS for ORKA to achieve its bar of ~50% maintenance of PASI-100 for patients in the off-treatment arm which would support annual dosing in some patients with

Form 4 Oruka Therapeutics, Inc. For: Oct 01 Filed by: Klein Lawrence Otto

Fri, 02 Oct 2026 19:55:00 -0400

si-local-file:///var/storage/secattach/20261002/27144061.html

Form 144 Oruka Therapeutics, Inc. Filed by: Klein Lawrence Otto

Thu, 01 Oct 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20261001/27136301.html

H.C. Wainwright Reiterates Buy Rating on Oruka Therapeutics (ORKA)

Thu, 24 Sep 2026 06:47:16 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $120.00 price target on Oruka Therapeutics (NASDAQ: ORKA).

The analyst commented: "Phase 2a EVERLAST-A showed PASI 100 increasing to 71.4% (45/63) at Week 28 from 63.5% (40/63) at Week 16, while PASI 90 increased to 87.3% (55/63) from 82.5%, following 600mg doses at Weeks 0 and 4. The 7.9-point improvement in complete clearance occurred without additional dosing, strengthening the evidence that extending treatment intervals can preserve and deepen efficacy. Blinded placebo crossovers also achieved 40.0% PASI 100 after 12 weeks of treatment vs. 42.9% in the original active cohort at

Oruka's ORKA-001 shows deepening psoriasis response at week 28

Wed, 23 Sep 2026 07:02:37 -0400

Oruka Therapeutics (Nasdaq: ORKA) reported Week 28 data from its EVERLAST-A Phase 2a trial of ORKA-001, an IL-23p19 monoclonal antibody being evaluated for moderate-to-severe plaque psoriasis, according to a company press release.

The trial enrolled 84 patients randomized 3:1 to receive 600 mg of ORKA-001 at Week 0 and Week 4, or matching placebo, across 26 sites in the United States and Canada. Patients initially receiving placebo crossed over to receive 600 mg of ORKA-001 at Weeks 16 and 20.

Among the 63 patients treated with ORKA-001 in the active arm, PASI 100 response rates rose to 71.4% at Week 28, up

Oruka's ORKA-001 shows deepening psoriasis response at week 28

Wed, 23 Sep 2026 07:02:37 -0400

Among the 63 patients treated with ORKA-001 in the active arm, PASI 100 response rates rose to 71.4% at Week 28, up

Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

Wed, 23 Sep 2026 07:00:00 -0400

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4

Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001

ORKA-001 maintained a favorable safety and tolerability profile through Week 28

52-week EVERLAST-A data for all patients expected in December 2026

16-week EVERLAST-B data expected in 4Q 2026

MENLO PARK, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a

Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

Wed, 23 Sep 2026 07:00:00 -0400

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4

Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001

ORKA-001 maintained a favorable safety and tolerability profile through Week 28

52-week EVERLAST-A data for all patients expected in December 2026

16-week EVERLAST-B data expected in 4Q 2026

MENLO PARK, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a

Form 4 Oruka Therapeutics, Inc. For: Sep 21 Filed by: Agarwal Arjun

Mon, 21 Sep 2026 17:39:00 -0400

si-local-file:///var/storage/secattach/20260921/27086167.html

Form 4 Oruka Therapeutics, Inc. For: Sep 21 Filed by: Quinlan Paul T

Mon, 21 Sep 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260921/27085913.html

Form 144 Oruka Therapeutics, Inc. Filed by: Agarwal Arjun

Mon, 21 Sep 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260921/27085632.html

Form 4 Oruka Therapeutics, Inc. For: Sep 15 Filed by: Goncalves Joana

Tue, 15 Sep 2026 19:19:00 -0400

si-local-file:///var/storage/secattach/20260915/27066146.html

Form 4 Oruka Therapeutics, Inc. For: Sep 11 Filed by: Agarwal Arjun

Tue, 15 Sep 2026 19:17:00 -0400

si-local-file:///var/storage/secattach/20260915/27066145.html

Form 4 Oruka Therapeutics, Inc. For: Sep 15 Filed by: Klein Lawrence Otto

Tue, 15 Sep 2026 19:15:00 -0400

si-local-file:///var/storage/secattach/20260915/27066143.html

Form 4 Oruka Therapeutics, Inc. For: Sep 15 Filed by: Quinlan Paul T

Tue, 15 Sep 2026 19:14:00 -0400

si-local-file:///var/storage/secattach/20260915/27066139.html

Form 4 Oruka Therapeutics, Inc. For: Sep 15 Filed by: Sandler Laura Lee

Tue, 15 Sep 2026 19:12:00 -0400

si-local-file:///var/storage/secattach/20260915/27066137.html

Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference

Wed, 09 Sep 2026 16:01:00 -0400

MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its attendance at the 2026 Morgan Stanley Global Healthcare Conference, taking place in New York, NY from September 14-16, 2026.

About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like

Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference

Wed, 09 Sep 2026 16:01:00 -0400

H.C. Wainwright Reiterates Buy Rating on Oruka Therapeutics (ORKA)

Thu, 03 Sep 2026 06:55:29 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $120.00 price target on Oruka Therapeutics (NASDAQ: ORKA).

The analyst commented: 'Late last month, Oruka Therapeutics announced the appointment of Todd Edwards as Chief Commercial Officer. Mr. Edwards brings more than 25 years of commercial leadership experience across immunology and dermatology, spanning both biologics and topical therapies. He previously led the transformation of the ZORYVE (roflumilast) franchise across multiple inflammatory skin diseases—rebuilding the psoriasis (PsO) commercial organization, launching new indications in atopic dermatitis and seborrheic dermatitis, and delivering consistent revenue growth. From our vantage point, this announcement demonstrates Oruka's intent

Form 424B5 Oruka Therapeutics, Inc.

Fri, 28 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260828/26997982.html

Form 424B5 Oruka Therapeutics, Inc.

Fri, 28 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260828/26997982.html